menu
    • menu
    [{"orgOrder":0,"company":"MUHC Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MUHC Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MUHC Foundation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MUHC Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Pulmonem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pulmonem \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ Inapplicable"},{"orgOrder":0,"company":"Pulmonem","sponsor":"Mcgill University Health Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pulmonem \/ Mcgill University Health Centre","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ Mcgill University Health Centre"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"Pulmonem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"McGill University Health Centre Research Institute \/ Pulmonem","highestDevelopmentStatusID":"10","companyTruncated":"McGill University Health Centre Research Institute \/ Pulmonem"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"SeegPharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Cosette Pharma \/ SeegPharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ SeegPharm"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Universitaire Ziekenhuizen KU Leuven","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sulfadiazine","moa":"||Bacterial dihydropteroate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw | Universitaire Ziekenhuizen KU Leuven","highestDevelopmentStatusID":"10","companyTruncated":"Radboud University Medical Center \/ ZonMw | Universitaire Ziekenhuizen KU Leuven"},{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSIDS Research Foundation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Research Foundation \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Dapsone (USP)

    Menu

    Dapsone (USP)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cosette Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : SeegPharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone 5%

                            Details : Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.

                            Product Name : Aczone-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 13, 2023

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : SeegPharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radboud University Medical Center

                            Country arrow
                            EPSC
                            Not Confirmed

                            Radboud University Medical Center

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfadiazine,Dapsone

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : ZonMw | Universitaire Ziekenhuizen KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Perioperative SDD to Prevent Infectious Complications After Esophagectomy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 19, 2023

                            Lead Product(s) : Sulfadiazine,Dapsone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : ZonMw | Universitaire Ziekenhuizen KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pulmonem

                            Canada arrow
                            EPSC
                            Not Confirmed

                            Pulmonem

                            Canada arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Promising COVID-19 Therapeutic Drug to start Phase 3 Clinical Trial in the United States

                            Details : PULM-001 data shown to prevent and treat acute respiratory distress syndrome due to SARS-CoV-2 infection and reduce mortality from 40% to 0% in a small, randomized clinical trial.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 22, 2021

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            McGill University Health Centre Research Institute

                            Country arrow
                            EPSC
                            Not Confirmed

                            McGill University Health Centre Research Institute

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Pulmonem

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 23, 2021

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Pulmonem

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MUHC Foundation

                            Country arrow
                            EPSC
                            Not Confirmed

                            MUHC Foundation

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III North American Clinical Trial for COVID-19 Treatment begins after FDA & Health Canada approval

                            Details : PULM-001 is a decades-old, safe and affordable oral antibacterial that also has well-recognized anti-inflammatory properties. It has been used to treat infectious diseases such as malaria, lupus, HIV and many other inflammatory infections.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 14, 2021

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MSIDS Research Foundation

                            Country arrow
                            EPSC
                            Not Confirmed

                            MSIDS Research Foundation

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Doxycycline,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MSIDS Research Foundation Study Finds That Leprosy Drugs Provide Potential Cure for Chronic Lyme Disease

                            Details : Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 28, 2020

                            Lead Product(s) : Dapsone,Doxycycline,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pulmonem

                            Canada arrow
                            EPSC
                            Not Confirmed

                            Pulmonem

                            Canada arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Mcgill University Health Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New COVID-19 Drug Therapy Developed by Canadian Biotech Start-up Headed for Phase III Clinical Trial Sponsored...

                            Details : The Phase III Clinical Trial is sponsored by the Research Institute of the McGill University Health Centre (RI-MUHC) and will be conducted in seven centres in Canada and the United States as soon as the necessary funding has been secured.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 09, 2020

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Mcgill University Health Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Torrent Pharmaceuticals Limited

                            India arrow
                            EPSC
                            Not Confirmed

                            Torrent Pharmaceuticals Limited

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Catawba Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 11, 2019

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Catawba Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Taro Pharmaceutical Industries

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 27, 2017

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Almirall

                            Spain arrow
                            EPSC
                            Not Confirmed

                            Almirall

                            Spain arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Allergan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 09, 2016

                            Lead Product(s) : Dapsone,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Allergan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth